Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 49 | ECE2017 | Next issue

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

Card image cap
20-23 May 2017, Lisbon, Portugal Further information

Oral Communications

Cardiovascular endocrinology (1)

ea0049oc7.1 | Cardiovascular endocrinology (1) | ECE2017

Estrogens enhance gonadectomy-induced adrenocortical tumor progression in mice

Chrusciel Marcin , Doroszko Milena , Jakobi Meike , Brouze Michal , Ponikwicka-Tyszko Donata , Bernaczyk Piotr , Anisimowicz Slawomir , Wolczynski Slawomir , Toppari Jorma , Huhtaniemi Ilpo , Rahman Nafis

Prepubertally gonadectomized (GDX) wild-type DBA/2J mice develop adrenocortical neoplasms presenting with small spindle-shaped non steroidogenic A-cells and large lipid-laden, steroidogenic and mitotically active B-cells. Neoplastic B-cells overexpress estrogen receptor α (ERα, Ers1) and β (ERβ, Ers2), aromatase (CYP19a1) and produce sex-steroids, resembling gonadal rest tissue. To test the role of estrogen-ER system in adrenocortical tumor progression, GDX...

ea0049oc7.2 | Cardiovascular endocrinology (1) | ECE2017

Targeted molecular markers derived from genomic classification for adrenocortical cancer prognostication

Jouinot Anne , Assie Guillaume , Fassnacht Martin , Libe Rossella , Dousset Bertrand , Ronchi Silviu Sbiera Cristina , Kroiss Matthias , Korpershoek Esther , De Krijger Ronald , Waldmann Jens , Quinkler Marcus , Tabarin Antoine , Chabre Olivier , Luconi Michaela , Mannelli Massimo , Groussin Lionel , Baudin Eric , Amar Laurence , Beuschlein Felix , Bertherat Jerome

Background: Adrenocortical cancer (ACC) is an aggressive tumour with heterogeneous prognosis. Recently integrated genomics reported distinct genomic alterations: transcriptome “C1A” (high expression of proliferation/cell cycle-related genes) vs “C1B”, “CIMP” (CpG islands hypermethylation) vs “non-CIMP”, chromosome alterations “Noisy” (numerous and anarchic alterations) vs “Chromosomal” (extended patterns of loss of he...

ea0049oc7.3 | Cardiovascular endocrinology (1) | ECE2017

High Total 68Ga-DOTATATE-Avid Tumor Volume (TV) is associated with low progression-free survival and high disease-specific mortality rate in patients with neuroendocrine tumors

Tirosh Amit , Papadakis Georgios Z. , Millo Corina , Sadowski Samira M. , Herscovitch Peter , Pacak Karel , Marx Stephen J. , Yang Lily , Nockel Pavel , Shell Jasmine , Green Patience , Keutgen Xavier M. , Patel Dhaval , Nilubol Naris , Kebebew Electron

Background: Patients with neuroendocrine tumors (NETs) have divergent survival, even when having the same site of primary tumor, and tumor stage and grade. 68Gallium (68Ga)-DOTATATE positron emission tomography (PET)/computed tomography (CT) is a sensitive imaging modality for detecting NETs. The purpose of this study was to determine whether 68Ga-DOTATATE PET/CT imaging has any prognostic utility in patients with NETs.Methods: One hundred and eighty-fou...

ea0049oc7.4 | Cardiovascular endocrinology (1) | ECE2017

A novel insight into the anticancer mechanism of metformin in Pancreatic Neuroendocrine Tumor cells

Vitali Eleonora , Piccinini Sara , Boemi Ilena , Tresoldi Alberto , Zerbi Alessandro , Carnaghi Carlo , Spada Anna , Lania Andrea

Metformin (1.1-dimethylbiguanide hydrochloride), a widely used antidiabetic drug, has been reported to display potent anticancer properties in various types of cancers, including neuroendocrine tumors. Recently, a potential synergistic activity between metformin and octreotide (SSA) in Pancreatic Neuroendocrine Tumors (P-NETs) has been proposed. AIP (aryl hydrocarbon receptor-interacting protein) acts as tumor suppressor gene in neuroendocrine tumors at pituitary level and it ...

ea0049oc7.5 | Cardiovascular endocrinology (1) | ECE2017

Regulation of steroid receptor signalling by tumor suppressor INPP4B

Zhang Manqi , Suarez Egla , Nathanson Lubov , Ittmann Michael , Weigel Nancy , Agoulnik Irina

Androgen receptor (AR) signaling is the main driver for prostate cancer progression and androgen ablation is the treatment of choice for tumors that spread beyond the prostate. Efficient at first, androgen ablation fails due in part to altered cell signaling and expression of AR spice variants. Cell signaling in prostate cancer is regulated by dual specificity phosphatases and tumor suppressors INPP4B and PTEN that are lost with prostate cancer progression. Loss of PTEN destab...